Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-06-06

Clinical Trial Update: Dysport in the Treatment of Glabellar Lines in Chinese Subjects [Phase 3]

View source ↗

Summary

Phase 3 trial update for Dysport in treating glabellar lines in Chinese subjects has completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Dysport (abobotulinumtoxinA)

Snippet

Sponsor: Ipsen | Conditions: Glabellar Lines | Phase 3 | Status: COMPLETED | Results posted: 2019-06-06